B&K Corporation (HKG:2396) said it enrolled the first patient in the phase 3a clinical trial of Pro-101-1 to treat deep second-degree burns, according to a Tuesday filing with the Hong Kong bourse.
The biopharmaceutical company shares fell 1% in morning trade Wednesday.
Pro-101-1 is one of the core products of the company.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments